Enlivex Reports $1.95B H1 Net Income on $2.55B Non-Cash Digital Asset Gains
ENLV is trading near its 52-week low of $0.57 (4.2% above the low).
Summary
Enlivex reported $1.95B in H1 2026 net income, but nearly all of it came from non-cash unrealized gains on its RAIN digital asset holdings and purchase option. Core clinical operations lost $15.8M.
Key Events · Earnings and Guidance · ENLV
-
H1 Net Income of $1.95B
Six-month net income of $1.949B (Q2: $1.892B) was driven by $2.55B in non-cash unrealized gains on RAIN digital assets ($609.8M) and the RAIN Option fair value change ($1.944B).
-
Core Operating Loss Widens
Operating loss grew 139% to $15.8M for H1 2026 from $6.6M a year earlier, with R&D expenses up 41% to $6.6M and G&A up 387% to $9.2M on higher equity award costs.
-
Digital Asset Treasury Concentration
RAIN tokens valued at $1.25B and the RAIN Option at $3.63B together represent substantially all of the company's $4.9B total assets, creating extreme concentration risk to a single digital asset.
-
Deferred Tax Liability of $969.9M
The company recognized $587.3M in deferred tax expense for H1 2026 on unrealized digital asset gains, creating a $969.9M non-current deferred tax liability on the balance sheet.
Analysis · ENLV · Life Sciences
Enlivex's Q2 2026 financials reveal a company whose reported earnings are almost entirely driven by mark-to-market gains on its RAIN token treasury and the related purchase option — not by its core osteoarthritis drug development business. The $1.95B six-month net income masks a $15.8M operating loss from clinical operations. The balance sheet now carries a $3.63B derivative asset (the RAIN Option) and a $969.9M deferred tax liability, both highly sensitive to RAIN token price volatility. With the stock trading near its 52-week low at $0.59 and a market cap of only ~$10.4M, the disconnect between reported book value and market valuation is extreme. The filing also confirms the company regained Nasdaq compliance after the July reverse split, but the underlying business remains pre-revenue with ongoing cash burn.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $0.57 to $27.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.